[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Chang DK, Lin CT, Wu CH, Wu HC: A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One; 2009;4(1):e4171
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
  • Lung cancer is the leading cause of cancer-related mortality worldwide.
  • However, a ligand-mediated drug delivery system should be able to render chemotherapy more specific to tumor cells and less toxic to normal tissues.
  • In this study, we isolated a novel peptide ligand from a phage-displayed peptide library that bound to non-small cell lung cancer (NSCLC) cell lines.
  • The targeting phage bound to several NSCLC cell lines but not to normal cells.
  • When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased.
  • Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin.
  • The current study suggests that this tumor-specific peptide may be used to create chemotherapies specifically targeting tumor cells in the treatment of NSCLC and to design targeted gene transfer vectors or it may be used one in the diagnosis of this malignancy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Delivery Systems / methods. Lung Neoplasms / drug therapy. Peptides / administration & dosage
  • [MeSH-minor] Animals. Bacteriophages / immunology. Cell Line, Tumor. Disease Models, Animal. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Humans. Ligands. Liposomes. Mice. Mice, SCID. Peptide Library. Tissue Distribution / drug effects. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1029-33 [11038041.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):243-54 [11234875.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):149-68 [11259838.001]
  • [Cites] Oncology. 2001;61 Suppl 1:3-13 [11598409.001]
  • [Cites] Eur J Cancer. 2001 Dec;37 Suppl 9:S15-8 [11741769.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):413-8 [11839657.001]
  • [Cites] Breast Cancer Res. 2002;4(3):95-9 [12052251.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):750-63 [12360278.001]
  • [Cites] J Gen Virol. 2003 Oct;84(Pt 10):2771-9 [13679612.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):721-9 [14662428.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] J Infect Dis. 2004 Aug 15;190(4):797-809 [15272409.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] Science. 1985 Jun 14;228(4705):1315-7 [4001944.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Clin Pharmacokinet. 1988 Jul;15(1):15-31 [3042244.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4478-84 [2369726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6774-81 [1458465.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3752-6 [7641188.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):1029-37 [7490617.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1657-60 [7502074.001]
  • [Cites] Nature. 1996 Mar 28;380(6572):364-6 [8598934.001]
  • [Cites] Ann Biomed Eng. 1996 Jul-Aug;24(4):457-73 [8841721.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] Br J Cancer. 1997;75(4):482-6 [9052397.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Mar;280(3):1406-14 [9067330.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Virology. 1997 Oct 27;237(2):319-26 [9356343.001]
  • [Cites] Drugs. 1997;54 Suppl 4:15-21 [9361957.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1195-201 [9515805.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):430-7 [9664085.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):83-94 [9918206.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8002-8 [15520208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7 [16123131.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9 [16203786.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10073-82 [17047071.001]
  • [Cites] Clin Vaccine Immunol. 2007 Apr;14(4):404-11 [17287314.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10958-65 [18006841.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):579-89 [18347144.001]
  • (PMID = 19137069.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Liposomes; 0 / Peptide Library; 0 / Peptides; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2614347
  •  go-up   go-down


2. Karp DD, Tsao AS, Kim ES: Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg; 2003 Oct;15(4):405-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsmall-cell lung cancer: chemoprevention studies.
  • Lung cancer is the leading cause of cancer-related death in the world.
  • Tobacco is an addictive agent producing carcinogenic effects that have been extremely difficult to prevent or detect in a curable stage.
  • It is critical to remember that lung cancer is usually diagnosed decades after the patient has begun or even stopped smoking.
  • We must intervene with more effective agents or combinations of agents and do it earlier in the process of carcinogenesis.
  • Approximately 10% of patients with lung cancer either never smoked or only were "passive" smokers due to their environment, workplace.
  • We now have unprecedented knowledge regarding the control of cellular growth and senescence.
  • New diagnostic tools also allow detection of smaller lesions.
  • We must use all our knowledge of the cancer biology, new risk models, more refined intermediate markers, and modern detection tools to focus more clearly on the pathology of lung cancer and design research to ask more probing and relevant questions so we can begin to put an end to the worldwide scourge of this terrible killer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / prevention & control. Lung Neoplasms / prevention & control
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / prevention & control. Primary Prevention. Randomized Controlled Trials as Topic. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14710383.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 152
  •  go-up   go-down


3. Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D: Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomedicine; 2011;6:59-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.
  • The ligands found by this technique, such as peptides, have been successfully applied in the fields of early cancer diagnostics and chemotherapy.
  • In this study, a novel nonsmall cell lung cancer-targeting peptide (LCTP, sequence RCPLSHSLICY) was screened in vivo using a Ph.D.
  • In order to develop a universal tumor-targeting drug carrier, the LCTP and fluorescence-labeled molecule (FITC) were conjugated to an acetylated polyamidoamine (PAMAM) dendrimer of generation 4 (G4) to form a PAMAM-Ac-FITC-LCTP conjugate.
  • In vitro results of cell experiments analyzed by flow cytometry and inverted fluorescence microscopy indicated that PAMAM-Ac-FITC-LCTP was enriched more in NCI-H460 cells than in 293T cells, and cellular uptake was both time- and dose-dependent.
  • The tissue distribution of the conjugate in athymic mice with lung cancer xenografts was also investigated to test the targeting efficiency of PAMAM-Ac-FITC-LCTP in vivo.
  • The results showed that LCTP can effectively facilitate the targeting of PAMAM-Ac-FITC-LCTP to nonsmall cell lung cancer cells and tumors.
  • These results suggest that the LCTP-conjugated PAMAM dendrimer might be a promising drug carrier for targeted cancer diagnosis and treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Dendrimers / chemistry. Drug Delivery Systems / methods. Lung Neoplasms / drug therapy. Peptides / pharmacokinetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Carriers / administration & dosage. Drug Carriers / chemistry. Drug Carriers / pharmacokinetics. Female. Fluorescein-5-isothiocyanate. Humans. Mice. Mice, Inbred BALB C. Peptide Library. Spectrophotometry, Ultraviolet. Tissue Distribution. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Nanomedicine. 2010;5:101-8 [20309396.001]
  • [Cites] J Control Release. 2010 Apr 2;143(1):2-12 [19925835.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):133-48 [10699277.001]
  • [Cites] Nat Med. 2002 Jul;8(7):751-5 [12053175.001]
  • [Cites] Science. 1985 Jun 14;228(4705):1315-7 [4001944.001]
  • [Cites] Methods Enzymol. 1987;143:115-9 [3657523.001]
  • [Cites] Science. 1990 Jul 27;249(4967):386-90 [1696028.001]
  • [Cites] Nature. 1996 Mar 28;380(6572):364-6 [8598934.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):542-6 [9181576.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):139-46 [15671538.001]
  • [Cites] Int J Pharm. 2005 May 13;295(1-2):221-33 [15848007.001]
  • [Cites] Chem Commun (Camb). 2005 Dec 14;(46):5739-41 [16307130.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):52-9 [16432162.001]
  • [Cites] Bioconjug Chem. 2006 Sep-Oct;17(5):1109-15 [16984117.001]
  • [Cites] J Pept Sci. 2007 May;13(5):348-53 [17436344.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):965-72 [17504878.001]
  • [Cites] Bioconjug Chem. 2007 Jul-Aug;18(4):1148-54 [17566976.001]
  • [Cites] Int J Nanomedicine. 2007;2(1):89-99 [17722516.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10958-65 [18006841.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):1756-62 [17970585.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):1739-48 [17907769.001]
  • [Cites] Bioconjug Chem. 2008 Jul;19(7):1396-403 [18576676.001]
  • [Cites] Int J Pharm. 2008 Aug 6;360(1-2):204-12 [18565704.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):392-7 [18648371.001]
  • [Cites] Mol Pharm. 2008 Jul-Aug;5(4):527-39 [18537262.001]
  • [Cites] Int J Nanomedicine. 2008;3(2):201-10 [18686779.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5494-502 [18765541.001]
  • [Cites] Nanomedicine (Lond). 2008 Oct;3(5):679-702 [18817470.001]
  • [Cites] Curr Top Med Chem. 2008;8(14):1237-85 [18855708.001]
  • [Cites] J Control Release. 2008 Oct 21;131(2):86-93 [18700158.001]
  • [Cites] Biomacromolecules. 2009 Jan 12;10(1):119-27 [19061333.001]
  • [Cites] J Transl Med. 2008;6:80 [19094226.001]
  • [Cites] Bioconjug Chem. 2008 Nov 19;19(11):2239-52 [18950215.001]
  • [Cites] Eur J Med Chem. 2009 Feb;44(2):862-8 [18550227.001]
  • [Cites] Int J Nanomedicine. 2009;4:1-7 [19421366.001]
  • [Cites] Mol Pharm. 2009 May-Jun;6(3):940-50 [19231841.001]
  • [Cites] Mol Pharm. 2009 Jul-Aug;6(4):1190-204 [19453158.001]
  • [Cites] Cancer Biomark. 2009;5(4):177-88 [19729827.001]
  • [Cites] Curr Pharm Des. 2009;15(25):2958-69 [19754372.001]
  • [Cites] BMC Cell Biol. 2009;10:63 [19740430.001]
  • [Cites] Int J Pharm. 2010 Jan 15;384(1-2):189-94 [19825406.001]
  • [Cites] Hum Gene Ther. 2010 Feb;21(2):191-8 [19788387.001]
  • [Cites] J Cell Mol Med. 2010 Jan;14(1-2):351-6 [20414975.001]
  • (PMID = 21289982.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dendrimers; 0 / Drug Carriers; 0 / PAMAM Starburst; 0 / Peptide Library; 0 / Peptides; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC3025585
  • [Keywords] NOTNLM ; in vivo phage display / nonsmall cell lung cancer / peptide / polyamidoamine dendrimer / targeted drug delivery
  •  go-up   go-down


Advertisement
4. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120. Drugs R D; 2004;5(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Motexafin gadolinium [gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120] is a radiosensitising agent developed for use in cancer therapy.
  • It is cytotoxic in haematological malignancies by selectively localising in cancer cells that have high rates of metabolism.
  • Motexafin gadolinium inhibits cellular respiration resulting in the production of reactive oxygen species and inducing apoptosis.
  • In June 2003, at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003), the importance of having an agent for the treatment of brain metastases from lung cancer was highlighted.
  • Results of a phase III study were presented that showed that motexafin gadolinium treatment was associated with a delay in time to neurological and neurocognitive progression in lung cancer patients.
  • This was an important finding, as 46.6% of lung cancer patients already have brain metastases at the time of initial diagnosis, compared with only 2.7% of breast cancer patients.
  • Brain metastases are also often the only site of metastatic disease in patients with lung cancer.
  • In December 2002, Pharmacyclics began a phase III trial of motexafin gadolinium in patients with brain metastases (brain cancer in phase table) from lung cancer in the US, Europe, Canada and Australia.
  • In addition, phase I trials are underway in children with intrinsic pontine glioma and adults with head and neck, lung and pancreatic cancers.
  • The first trial, conducted in patients with stage IIIA non-small cell lung cancer, was designed to determine the safety of two different dosing regimens of motexafin gadolinium during preoperative radiotherapy after induction chemotherapy.
  • Two phase I clinical trials have also been conducted for the treatment of newly diagnosed glioblastoma multiforme at the UCLA Jonsson Comprehensive Cancer Center, USA.
  • [MeSH-major] Drugs, Investigational / therapeutic use. Metalloporphyrins / therapeutic use. Neoplasms / drug therapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14725495.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Metalloporphyrins; 0 / Radiation-Sensitizing Agents; 6433A42F4F / motexafin gadolinium
  • [Number-of-references] 18
  •  go-up   go-down


5. Sun XR, Zheng Y, MacAulay C, Lam S, Doudkine A, Palcic B: In vitro model for studying malignancy associated changes. Anal Cell Pathol; 2003;25(2):95-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been postulated that MAC have a potential to become a useful tool in detection, diagnosis and prognosis of malignant diseases.
  • An in vitro cell culture model system was designed to study interactions between non-small cell lung cancer (NSCLC) and the normal bronchial epithelium of the human respiratory tract in vivo to see if the MAC-like phenomenon can be detected in such a system.
  • In this study we examined changes in nuclear features of normal human bronchial epithelial cells (NHBE) when they were co-cultured with cells derived from a lung cancer cell line NCI-H460.
  • [MeSH-major] Cell Transformation, Neoplastic. Neoplasms / diagnosis. Neoplasms / pathology. Tumor Cells, Cultured
  • [MeSH-minor] Bronchi / metabolism. Carcinoma, Non-Small-Cell Lung / diagnosis. Cell Culture Techniques / methods. Cell Line, Tumor. Coculture Techniques. DNA / metabolism. Diploidy. Dose-Response Relationship, Drug. Epithelial Cells / pathology. Humans. Image Processing, Computer-Assisted. Lung Neoplasms / diagnosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12632019.001).
  • [ISSN] 0921-8912
  • [Journal-full-title] Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology
  • [ISO-abbreviation] Anal Cell Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC4618911
  •  go-up   go-down


6. Papadimitriou E, Polykratis A, Hatziapostolou M, Parthymou A, Polytarchou C, Mikelis C: Heparin affin regulatory peptide: a new target for tumour therapy? Curr Cancer Drug Targets; 2004 Sep;4(6):471-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A growing body of evidence indicates that HARP is involved in the control of cellular proliferation, migration and differentiation and plays a significant role in tumor growth and angiogenesis.
  • HARP has a well described role in physiological as well as tumor angiogenesis, and is detected in various carcinomas, such as human breast and prostate cancer, neuroblastomas, gliomas, benign meningiomas, small cell lung cancer and mammary tumors, exhibiting a proto-oncogene function.
  • It is also constitutively expressed in tumour cell lines and is involved in tumour growth and metastasis.
  • Therefore, HARP appears to be a potential new target for the treatment or/and diagnosis of several types of cancer.
  • [MeSH-major] Carrier Proteins / antagonists & inhibitors. Cytokines / antagonists & inhibitors. Drug Delivery Systems / methods. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Bentham Science Publishers Ltd.
  • (PMID = 15379633.001).
  • [ISSN] 1568-0096
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin
  • [Number-of-references] 106
  •  go-up   go-down


7. Junker K, Müller KM, Abker S, Bosse U, Klinke F, Thomas M: [Cellular changes in non-small cell lung cancer after neoadjuvant therapy]. Pathologe; 2004 May;25(3):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cellular changes in non-small cell lung cancer after neoadjuvant therapy].
  • Microscopic analysis of resection specimens of non-small cell lung cancer after neoadjuvant therapy evokes the subjective impression of cytologic changes, especially enlargement of the individual tumor cells and their nuclei.
  • The adenocarcinomas investigated revealed a significant cellular enlargement after treatment.
  • The cellular and nuclear parameters analysed as well as the cytomorphological changes assessed showed no significant correlation to the grade of therapy-induced tumor regression and thus do not allow an assessment of therapy success.
  • Based on these results, grading of non-small cell lung cancer is not recommended after neoadjuvant therapy and the diagnosis of "large cell anaplastic" carcinoma should be made with reservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Diagnosis, Differential. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 2000 Sep;21(5):358-63 [11092008.001]
  • [Cites] Br J Cancer. 1988 May;57(5):503-8 [3395555.001]
  • [Cites] APMIS. 1995 Jul-Aug;103(7-8):588-92 [7576577.001]
  • [Cites] Acta Cytol. 1993 May-Jun;37(3):353-7 [8388609.001]
  • [Cites] S Afr Med J. 1987 Jul 18;72(2):103-6 [3039671.001]
  • [Cites] Cancer. 1989 Feb 15;63(4):631-7 [2536583.001]
  • [Cites] Histopathology. 1986 May;10(5):461-75 [3013746.001]
  • [Cites] Pathologe. 1985 Jan;6(1):16-23 [3983083.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):335-41 [7914426.001]
  • [Cites] Chirurg. 2003 Jan;74(1):42-8; discussion 49 [12552404.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(9):469-77 [9341895.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1185 [10561177.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):192-8 [2155174.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1982 May;61(5):246-50 [6178922.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Mod Pathol. 1996 Sep;9(9):893-900 [8878021.001]
  • [Cites] Pathologe. 1985 Jan;6(1):3-7 [3983085.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Pathol Res Pract. 1997;193(3):187-96 [9198104.001]
  • [Cites] Pathologe. 1997 Mar;18(2):131-40 [9244871.001]
  • [Cites] Chest. 2001 Nov;120(5):1584-91 [11713138.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):408-16 [6185202.001]
  • (PMID = 15138700.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Cho WC: Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother; 2007 Oct;61(9):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer.
  • Lung cancer ranks top in both incidence and mortality in most part of the world.
  • Scientists strive to explore biomarkers and their possible role in the diagnosis, treatment and prognosis of lung cancer.
  • Highly elevated concentrations of cytokeratin 19 fragment, tissue polypeptide antigen and squamous cell carcinoma antigen in non-small cell lung cancer particularly for squamous cell carcinoma, carcinoembryonic antigen and cancer antigen 125 in adenocarcinoma or non-small cell lung cancer, as well as progastrin-releasing peptide and neuron specific enolase in small cell lung cancer are suggestive biomarkers for the malignancy.
  • Even with the report of high percent sensitivity and specificity, validation by clinical trials in large cohorts of patients is necessary before the cancer-related phenotypes can be translated into the clinic as reliable biomarkers.
  • Nevertheless, identifications of biomarkers are leading to more understanding of the molecular pathways involved in lung cancer.
  • It is hoped that understanding the connections between cellular pathways will help to reduce the suffering and loss of life caused by the lethal disease.
  • This article summarizes the pre-clinical and translational researches against lung cancer in relation to biomarker discovery and validation.
  • It is intended for policy makers, researchers, clinicians and other health professionals, offering a variety of useful biomarkers and updated data of clinical trials for lung cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Drug Monitoring. Humans. Neoplasm Recurrence, Local / diagnosis. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913444.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 57
  •  go-up   go-down


9. Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS, Zhang M: Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small; 2009 Feb;5(2):256-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles.
  • Nanoparticles have been investigated as drug delivery vehicles, contrast agents, and multifunctional devices for patient care.
  • Current nanoparticle-based therapeutic strategies for cancer treatment are mainly based on delivery of chemotherapeutic agents to induce apoptosis or DNA/siRNA to regulate oncogene expression.
  • Here, a nanoparticle system that demonstrates an alternative approach to the treatment of cancers through the inhibition of cell invasion, while serving as a magnetic resonance and optical imaging contrast agent, is presented.
  • The nanoparticle comprises an iron oxide nanoparticle core conjugated with an amine-functionalized poly(ethylene glycol) silane and a small peptide, chlorotoxin (CTX), which enables the tumor cell-specific binding of the nanoparticle.
  • It is shown that the nanoparticle exhibits substantially enhanced cellular uptake and an invasion inhibition rate of approximately 98% compared to unbound CTX ( approximately 45%).
  • Since upregulation and activity of MMP-2 have been observed in tumors of neuroectodermal origin, and in cancers of the breast, colon, skin, lung, prostate, ovaries, and a host of others, this nanoparticle system can be potentially used for non-invasive diagnosis and treatment of a variety of cancer types.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1999 Jul 15;19(14):5942-54 [10407033.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1667-70 [10356396.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):287-97 [15781315.001]
  • [Cites] J Am Chem Soc. 2005 Apr 27;127(16):5732-3 [15839639.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1755(1):37-69 [15907591.001]
  • [Cites] Nano Lett. 2005 Jun;5(6):1003-8 [15943433.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1418-23 [16244656.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] J Med Chem. 2006 Oct 5;49(20):6087-93 [17004722.001]
  • [Cites] Cell Mol Life Sci. 2007 Feb;64(4):458-78 [17260089.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):397-406 [17516742.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):13-24 [17520692.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6882-8 [17638899.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Small. 2008 Mar;4(3):372-9 [18232053.001]
  • [Cites] Nat Med. 2000 Mar;6(3):351-5 [10700241.001]
  • [Cites] Pflugers Arch. 2000 Oct;440(6):881-8 [11041554.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1241-4 [11689890.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1141-7 [11731783.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Glia. 2002 Aug;39(2):162-73 [12112367.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51 [12204596.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4135-44 [12454020.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4871-9 [9809993.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • (PMID = 19089837.001).
  • [ISSN] 1613-6829
  • [Journal-full-title] Small (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Small
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA119408-04; United States / NIGMS NIH HHS / GM / T32GM065098; United States / NIGMS NIH HHS / GM / T32 GM065098; United States / NCI NIH HHS / CA / 5R01CA11235; United States / NCI NIH HHS / CA / 5R01CA9408; United States / NIBIB NIH HHS / EB / R01EB006043; United States / NCI NIH HHS / CA / R01 CA112350; United States / NCI NIH HHS / CA / R01 CA119408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chlorotoxin; 0 / Peptides; 0 / RNA, Small Interfering; 0 / Scorpion Venoms; 9007-49-2 / DNA; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ NIHMS109549; NLM/ PMC2692352
  •  go-up   go-down


10. Natale RB: Inhibition of epidermal growth factor receptor and symptom improvement in advanced non-small cell lung cancer. Semin Respir Crit Care Med; 2004;25 Suppl 1:29-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of epidermal growth factor receptor and symptom improvement in advanced non-small cell lung cancer.
  • The majority of patients with non-small cell lung cancer (NSCLC) are not candidates for curative resection because of advanced disease at the time of diagnosis.
  • Any benefit derived from chemotherapy in this palliative setting must be balanced against the substantial toxicity associated with cytotoxic drugs.
  • Consequently, ZD1839 interrupts EGFR-mediated activities such as tumor cellular proliferation, motility, survival, and invasiveness.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088518.001).
  • [ISSN] 1069-3424
  • [Journal-full-title] Seminars in respiratory and critical care medicine
  • [ISO-abbreviation] Semin Respir Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA: Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest; 2006 Feb;129(2):393-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVES: 18F-fluorodeoxyglucose (FDG) is the most widely used positron emission tomography (PET) imaging probe used for the diagnosis, staging, restaging, and monitoring therapy response of cancer.
  • (1) to compare the use of FDG-PET and FLT-PET for tumor staging, (2) to compare the degree of FDG and FLT uptake in lung lesions, and (3) to determine the correlation between PET uptake intensity and tumor cell proliferation.
  • DESIGN: FDG-PET and FLT-PET scans were performed in 11 patients with solitary pulmonary nodules and another 11 patients with known non-small cell lung cancer (NSCLC).
  • Tumor cell proliferation was assessed by Ki-67 staining.
  • Nevertheless, the correlation between FLT uptake and cellular proliferation suggests that future studies should evaluate the use of FLT-PET for monitoring treatment with cytostatic anticancer drugs.
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Lymphatic Metastasis. Male. Neoplasm Staging. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478857.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


12. Hirata D, Yamabuki T, Miki D, Ito T, Tsuchiya E, Fujita M, Hosokawa M, Chayama K, Nakamura Y, Daigo Y: Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res; 2009 Jan 1;15(1):256-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.
  • PURPOSE: This study aims to isolate potential molecular targets for diagnosis, treatment, and/or prevention of lung and esophageal carcinomas.
  • EXPERIMENTAL DESIGN: We screened for genes that were frequently overexpressed in the tumors through gene expression profile analyses of 101 lung cancers and 19 esophageal squamous cell carcinomas (ESCC) by cDNA microarray consisting of 27,648 genes or expressed sequence tags.
  • In this process, we identified epithelial cell transforming sequence 2 (ECT2) as a candidate.
  • Tumor tissue microarray was applied to examine the expression of ECT2 protein in 242 archived non-small-cell lung cancers (NSCLC) and 240 ESCC specimens and to investigate its prognostic value.
  • A role of ECT2 in lung and esophageal cancer cell growth and/or survival was examined by small interfering RNA experiments.
  • Cellular invasive activity of ECT2 in mammalian cells was examined using Matrigel assays.
  • Knockdown of ECT2 expression by small interfering RNAs effectively suppressed lung and esophageal cancer cell growth.
  • In addition, induction of exogenous expression of ECT2 in mammalian cells promoted cellular invasive activity.
  • CONCLUSIONS: ECT2 cancer-testis antigen is likely to be a prognostic biomarker in clinic and a potential therapeutic target for the development of anticancer drugs and cancer vaccines for lung and esophageal cancers.
  • [MeSH-major] Biomarkers / analysis. Carcinoma, Non-Small-Cell Lung / diagnosis. Esophageal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Proto-Oncogene Proteins / analysis
  • [MeSH-minor] Aged. Base Sequence. Cell Line, Tumor. Disease Progression. Female. Humans. Male. Prognosis






Advertisement